<?xml version="1.0" encoding="UTF-8"?>
<p id="p0155">Recently, preliminary results of the RECOVERY trial involving dexamethasone (6Â mg given once daily for ten days) showed reduced mortality in patients receiving respiratory support (
 <xref rid="bib58" ref-type="bibr">Horby et al., 2020</xref>; 
 <xref rid="bib75" ref-type="bibr">Ledford, 2020</xref>). Dexamethasone reduced the mortality by one-third in patients receiving invasive mechanical ventilation and by one-fifth in patients receiving oxygen support without invasive mechanical ventilation. Whereas, no effect of the drug was noticed in patients in mild condition not requiring oxygen support (
 <xref rid="bib58" ref-type="bibr">Horby et al., 2020</xref>; 
 <xref rid="bib75" ref-type="bibr">Ledford, 2020</xref>). WHO also authorized the use of dexamethasone in severe to critical conditions only (
 <xref rid="bib149" ref-type="bibr">WHO, 2020</xref>).
</p>
